Key Insights• The Spain biosurgery market represents a significant and maturing national market for surgical biomaterials within Southern Europe. Valued at more than USD 212 million in 2025, the Spanish market is underpinned by a universal healthcare system, an advanced clinical infrastructure, and a substantial volume of surgical procedures. The market encompasses a broad range of biologically derived and bio-compatible materials including hemostatic agents, surgical sealants and adhesives, bone-graft substitutes, adhesion barriers, soft-tissue attachments, and staple-line reinforcement products that assist in surgical procedures by controlling bleeding, sealing tissues, promoting regeneration, and preventing postoperative complications.• The Spain biosurgery market is distinguished by its public healthcare system (Sistema Nacional de Salud, SNS), which provides universal coverage and serves as the primary purchaser and procurer of biosurgical products. Healthcare expenditure in Spain reached 10.7% of GDP in 2025, ranking the country 18th globally. Per capita health spending was approximately €3,137 in 2023, below the European Union average, with private health expenditure accounting for 26% of total spending in 2025. The market is shaped by a complex interplay of demographic trends, technological innovation, regulatory frameworks, and evolving healthcare delivery models, including the growing role of the private healthcare sector, which covers 29% of the most complex surgical interventions performed in the country.• Healthcare expenditure reached 10.7% of GDP, ranking Spain 18th globally.Bone-Graft Substitutes represent the largest product category within the Spanish biosurgery market, driven by the high volume of orthopedic procedures.

Hip and knee prostheses are among the most frequently performed surgeries, with knee arthroplasty and hip arthroplasty among the 11 surgical processes monitored by the Spanish health system.• Surgical Sealants and Adhesives represent the fastest-growing product category, driven by increasing adoption of minimally invasive surgical techniques across Spanish hospitals and private clinics. Private sector healthcare covers 29% of the most complex surgical interventions in Spain. Spain's aging population represents a significant long-term demand driver. For the first time, the population aged 65 and over has surpassed 10 million people, representing 20.7% of the total population. The aging index reached 148% in 2025, with 148 people aged 65 and over for every 100 children under 16.• The regulatory environment, centered on the European Medical Device Regulation (MDR) and the Spanish Agency for Medicines and Health Products (AEMPS), plays a decisive role in shaping market dynamics. Spain approved its first comprehensive national Health Technology Assessment (HTA) framework in May 2026, aligning with the EU HTAR.Market Outlook• According to the research report, "Spain Biosurgery Market Overview, 2031," published by Actual Market Research, the Spain Biosurgery market was valued at more than USD 151.63 Million in 2025. The Spanish biosurgery market is expected to maintain steady growth through 2031, supported by favorable demographic trends, ongoing technological innovation, and expanding surgical volumes across both public and private healthcare sectors.

The market's growth trajectory is intrinsically linked to the broader Spanish healthcare landscape, including healthcare expenditure, technological adoption, and demographic shifts.• The aging Spanish population represents the most significant long-term demand driver. With over 10 million people aged 65 and over (20.7% of the population), and projections indicating that the older population could exceed 15.9 million (29.2% of the total) by 2045, the incidence of age-related conditions requiring surgical intervention will increase correspondingly. The aging index reached 148% in 2025, the highest level of aging in Spain's history.• Technological innovation in biomaterials and surgical delivery systems is expanding the addressable market. Spain has approved its first comprehensive national HTA framework in May 2026, establishing a complete, transparent, and coordinated framework for evaluating medicines, medical devices, diagnostics, and clinical procedures. This framework introduces defined assessment timelines and emphasizes real-world evidence.• Rising surgical procedures are a key driver propelling market expansion. Over 853,000 patients were waiting for surgery at the end of 2025, with the 11 monitored surgical processes accounting for 295,275 patients.

The most demanded procedures include cataract surgery (124,194 patients), inguinal hernia repair (37,675 patients), and knee prosthesis (29,312 patients).Market DynamicsDriver: High Surgical Volumes and Aging PopulationSpain performs hundreds of thousands of surgical procedures annually across public hospitals, private clinics, and accredited facilities. Cataract surgery is the most frequently performed procedure with 124,194 patients waiting, followed by inguinal hernia repair (37,675) and knee prosthesis (29,312). The aging population with over 10 million people aged 65 and over (20.7% of the total) continues to drive demand for musculoskeletal and ophthalmic interventions. The aging index reached 148% in 2025, with 148 people aged 65 and over for every 100 children under 16. The proportion of people aged 65 and over has doubled from 10.2% in 1975 to 20.7% in 2025, while the proportion of those aged 80 and over has quadrupled. Healthcare expenditure of 10.7% of GDP provides the financial infrastructure to support expanding surgical volumes.Challenge: Waiting Lists and Healthcare Spending ConstraintsDespite significant healthcare investment, Spain faces persistent challenges that limit the full potential of the biosurgery market.

Over 853,000 patients were waiting for surgery at the end of 2025, with the longest average waiting times observed in plastic surgery (269 days), neurosurgery (172 days), and angiology and vascular surgery (151 days). Waiting lists remain a structural challenge, with more than 853,000 patients waiting for an operation, 20,000 more than six months earlier. Healthcare spending per capita of approximately €3,137 in 2023 is below the European Union average of over €4,000. Private health expenditure accounts for 26% of total spending, reflecting the role of private healthcare in addressing capacity constraints. Additionally, the public health budget faces pressures from an aging population and rising healthcare costs.Trend: Accelerating Adoption of Minimally Invasive and Robotic Surgical TechniquesThe Spanish biosurgery market is experiencing a significant trend toward minimally invasive and robotic surgical techniques. The Spanish Society of Laparoscopic Surgery has promoted the adoption of laparoscopic techniques, with many of the three hundred thousand surgeries performed in the 14 hospitals of the Castilla y León Regional Health Management being performed via this approach.

The private healthcare sector covers 29% of the most complex surgical interventions in Spain, including those utilizing advanced surgical platforms. This shift toward advanced surgical platforms creates new opportunities for biosurgical products specifically designed for minimally invasive applications. Surgical sealants and adhesives that can be delivered through small incisions, hemostatic agents optimized for sprayable application, and staple-line reinforcement products compatible with minimally invasive staplers are increasingly in demand. The continued adoption of these advanced techniques will shape product development and commercial strategies. Policies• The European Medical Device Regulation (MDR) (EU) 2017/745 serves as the core regulatory framework for biosurgical products in Spain. As an EU member state, Spain regulates medical devices primarily under EU-wide legislation, supplemented by national implementing laws.• The Spanish Agency for Medicines and Health Products (AEMPS) serves as the competent authority for medical devices in Spain, overseeing the implementation of the MDR and ensuring product safety and efficacy.• Royal Decree 192/2023 significantly updated Spain's regulatory framework for medical devices, establishing national registration requirements and implementing provisions of the MDR.• Royal Decree 90/2026 establishes the framework for selective public reimbursement and margins for the distribution and dispensing of medical devices for outpatients in the SNS, effective July 1, 2026.• Royal Decree 415/2026 was approved on May 27, 2026, establishing Spain's first comprehensive national HTA framework covering medicines, medical devices, diagnostics, and clinical procedures, aligning with the EU HTAR.• The National Health System (SNS) procurement policies play a pivotal role in shaping the Spanish biosurgery market, with centralized and regional tenders influencing pricing and adoption rates across public hospitals.Segment AnalysisSpain Biosurgery Market By Product• Bone-Graft Substitutes represent the largest product category within the Spanish biosurgery market, driven by the high volume of orthopedic procedures. Knee arthroplasty and hip arthroplasty are among the 11 surgical processes monitored by the Spanish health system, with knee prosthesis accounting for 29,312 patients.

These products include demineralized bone matrix (DBM), synthetic bone grafts, and biologic grafts incorporating growth factors. The aging Spanish population with over 10 million people aged 65 and over (20.7% of the total) continues to drive demand for musculoskeletal interventions requiring bone-graft substitutes.• Hemostatic Agents constitute a major market segment, reflecting their essential role across all surgical disciplines. These products including topical hemostats, flowable matrices, fibrin sealants, and thrombin-based agents are utilized in virtually every surgical procedure to control intraoperative bleeding. The increasing volume of surgeries and growing demand for effective hemostatic solutions contribute to the strength of this segment.• Surgical Sealants and Adhesives represent the fastest-growing product category in the Spanish biosurgery market, driven by increasing adoption of minimally invasive and robotic surgical techniques. These products including fibrin sealants, synthetic polymer-based sealants, and protein-based adhesives are used to seal tissue surfaces, prevent fluid and air leaks, and reinforce surgical anastomoses. The private healthcare sector's coverage of complex surgical interventions and the adoption of laparoscopic techniques support the expansion of this segment.• Adhesion Barriers represent a clinically important product category used to prevent postoperative adhesion formation in abdominal, pelvic, and gynecological surgeries.

The category continues to benefit from ongoing product innovation and clinical evidence supporting adhesion prevention, particularly as the volume of gynecological and abdominal procedures remains substantial.• Soft-Tissue Attachments encompass products used to reinforce, repair, or secure soft tissues, including surgical meshes, biologic scaffolds, and tissue grafts. These products are utilized in hernia repair, pelvic floor reconstruction, and various other soft-tissue procedures. Inguinal hernia repair is among the most demanded procedures, with 37,675 patients.• Staple-Line Reinforcement products are utilized in gastrointestinal, bariatric, and thoracic procedures to strengthen tissue interfaces along surgical staple lines, reducing the risk of bleeding and leakage. The increasing volume of thoracic and gastrointestinal procedures supports steady demand for these products.Spain Biosurgery Market By Application• Orthopedic Surgery is the largest application area for biosurgical products in Spain, driven by the high volume of joint replacement and trauma procedures. Knee and hip arthroplasties are among the 11 surgical processes monitored, with knee prosthesis accounting for 29,312 patients. The aging Spanish population with 20.7% aged 65 and over continues to drive demand for musculoskeletal interventions.• General Surgery encompasses a broad range of abdominal, gastrointestinal, and soft-tissue procedures, including inguinal hernia repair, cholecystectomy, and bariatric surgery.

Inguinal hernia repair accounts for 37,675 patients. General and Digestive Surgery follows orthopedics in the volume of complex interventions performed.• Cardiovascular Surgery represents the fastest-growing application area in the Spanish biosurgery market, driven by the high prevalence of cardiovascular disease in the aging population. Coronary bypass and valvular cardiac surgery are among the 11 surgical processes monitored. The private healthcare sector covers 29% of the most complex cardiovascular interventions.• Neurological Surgery utilizes biosurgical products particularly hemostatic agents and dural sealants to manage bleeding and prevent cerebrospinal fluid leaks. Neurosurgery has an average waiting time of 172 days, reflecting the high demand for neurological interventions. The aging population and increasing incidence of neurological conditions drive demand in this specialty.• Reconstructive Surgery involves the use of biosurgical products to restore, repair, or reconstruct damaged or surgically altered tissues.

Plastic surgery has the longest average waiting time of 269 days, reflecting significant demand for reconstructive procedures following trauma, disease, or surgery.• Gynecological Surgery includes biosurgical applications in procedures involving the female reproductive system, with products used for hemostasis, tissue sealing, adhesion prevention, tissue repair, and reinforcement. Hysterectomy is among the 11 surgical processes monitored by the Spanish health system.• Urological Surgery covers biosurgical applications in procedures involving the urinary tract and male reproductive system, with products used for bleeding control, tissue sealing, reinforcement, repair, and prevention of postoperative complications.• Thoracic and Other Surgeries represent a growing application area, driven by increasing adoption of video-assisted thoracoscopic surgery (VATS) and the rising burden of lung cancer and other thoracic conditions.Spain Biosurgery Market By Source/Origin• Biologic products represent the largest source category in the Spanish biosurgery market, driven by their superior biocompatibility and natural healing properties. These products include demineralized bone matrix, fibrin sealants, collagen hemostats, allografts, and xenografts. The MDR's rigorous requirements for biological materials ensure high safety standards and support market confidence.• Synthetic and Semi-Synthetic products represent the fastest-growing source category in the Spanish market, driven by cost-effectiveness, consistent quality, lower immunogenicity risks, and longer shelf life. These products include synthetic bone substitutes, PEG-based sealants, synthetic meshes, and polysaccharide hemostats. The Spanish healthcare system's emphasis on cost-effectiveness favors synthetic alternatives for certain applications.Spain Biosurgery Market By End-User• Hospitals remain the largest end-user segment for biosurgical products in Spain, accounting for the majority of revenue.

Public hospitals under the SNS perform the majority of surgical procedures in Spain. The 11 monitored surgical processes accounted for 295,275 patients. The concentration of complex surgical procedures and availability of specialized surgical teams make hospitals the primary setting for biosurgical product utilization. Private hospitals cover 29% of the most complex surgical interventions.• Ambulatory Surgical Centers (ASCs) represent the fastest-growing end-user segment in the Spanish biosurgery market, driven by the broader healthcare industry shift toward outpatient and same-day discharge models. The expansion of outpatient surgical capacity, supported by both public and private healthcare sectors, supports the adoption of biosurgical products in these settings.• Clinics represent a growing end-user segment, with specialty clinics performing eligible surgical or minimally invasive procedures utilizing biosurgical products for tissue repair, bleeding control, and sealing.Market Outlook by Infrastructure, Investment and Industry Development• The Spanish biosurgery market operates within a universal healthcare system managed through the Sistema Nacional de Salud (SNS) and 17 autonomous communities, creating regional variation in procurement and reimbursement. Healthcare expenditure reached 10.7% of GDP in 2025, while per-capita spending was approximately €3,137 in 2023, below the EU average; private healthcare accounted for 26% of total spending.

The new HTA framework under Royal Decree 415/2026 introduces mandatory evaluations for pricing and reimbursement, with maximum assessment timelines of 140 days for non-pharmacological technologies. Manufacturers must demonstrate clinical efficacy, cost-effectiveness, and real-world value.• Procurement combines regional health authority tenders, hospital agreements, and surgeon preferences, with regional consolidation increasing pricing competition. Manufacturers must navigate purchasing requirements across Spain’s 17 autonomous communities, supported by established national distribution networks. Royal Decree 90/2026 establishes a framework for selective public reimbursement and medical-device distribution margins, effective July 1, 2026. Spain has extensive public hospitals, private clinics, and accredited facilities, while the private sector performs approximately 29% of the country’s most complex surgical interventions. However, more than 853,000 patients remain on surgical waiting lists, creating both capacity challenges and opportunities for efficiency-enhancing technologies.• Spain has a large, highly trained surgical workforce supported by professional organizations, research institutions, and teaching hospitals.

Investment in biosurgery innovation is encouraged by the country’s research ecosystem and increasing emphasis on real-world evidence and patient participation under the new HTA framework. The regulatory environment follows the European MDR and national requirements including Royal Decree 192/2023 and Royal Decree 90/2026, with AEMPS serving as the competent authority. These frameworks provide rigorous safety and quality standards while establishing clearer processes for market access and technology evaluation.• Technology adoption is expanding across minimally invasive surgery, advanced biomaterials, and other innovative surgical platforms, supported by both public and private healthcare providers. Spain’s aging population provides a strong long-term demand driver, with more than 10 million people aged 65 and older, representing 20.7% of the population, while this group is projected to exceed 15.9 million, or 29.2%, by 2045. The Spanish biosurgery market was valued at more than USD 212 million in 2025. Rising surgical demand, healthcare investment, innovation, and evolving HTA processes create significant opportunities for manufacturers able to manage regional procurement, reimbursement, and regulatory requirements.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Biosurgery Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Product• Bone-Graft Substitutes• Hemostatic Agents• Surgical Sealants & Adhesives• Adhesion Barriers• Soft-Tissue Attachments• Staple-Line ReinforcementBy Application:• Orthopedic Surgery • General Surgery • Neurological Surgery • Cardiovascular Surgery • Reconstructive Surgery • Gynecological Surgery • Urological Surgery • Other surgeries (Thoracic surgeries & more)By Source/Origin• Biologic• Synthetic / Semi-syntheticBy End-user:• Hospitals • Ambulatory Surgical Centers • Clinics • Others.